tiprankstipranks
Karuna Therapeutics (KRTX)
NASDAQ:KRTX
US Market

Karuna Therapeutics (KRTX) Stock Forecast & Price Target

457 Followers
See the Price Targets and Ratings of:

KRTX Analyst Ratings

Hold
15Ratings
0 Buy
15 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Karuna
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KRTX Stock 12 Month Forecast

Average Price Target

$330.00
▲(0.06% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Karuna Therapeutics in the last 3 months. The average price target is $330.00 with a high forecast of $330.00 and a low forecast of $330.00. The average price target represents a 0.06% change from the last price of $329.79.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"173":"$173","252":"$252","331":"$331","212.5":"$212.5","291.5":"$291.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":330,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$330.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":330,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$330.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":330,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$330.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[173,212.5,252,291.5,331],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,316.24,317.29846153846154,318.35692307692307,319.4153846153846,320.4738461538462,321.5323076923077,322.59076923076924,323.64923076923077,324.7076923076923,325.7661538461538,326.8246153846154,327.88307692307694,328.94153846153847,{"y":330,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,316.24,317.29846153846154,318.35692307692307,319.4153846153846,320.4738461538462,321.5323076923077,322.59076923076924,323.64923076923077,324.7076923076923,325.7661538461538,326.8246153846154,327.88307692307694,328.94153846153847,{"y":330,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,316.24,317.29846153846154,318.35692307692307,319.4153846153846,320.4738461538462,321.5323076923077,322.59076923076924,323.64923076923077,324.7076923076923,325.7661538461538,326.8246153846154,327.88307692307694,328.94153846153847,{"y":330,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":191.63,"date":1679011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.46,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.16,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.65,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.69,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.38,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.7,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.13,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.42,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.53,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":316.25,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":314.88,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":316.24,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$330.00Average Price Target$330.00Lowest Price Target$330.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners
$330.00
Hold
0.06%
Upside
Downgraded
12/22/23
Karuna Therapeutics downgraded to Market Perform from Outperform at LeerinkKaruna Therapeutics downgraded to Market Perform from Outperform at Leerink
William Blair
Hold
Downgraded
12/22/23
Karuna Therapeutics downgraded to Market Perform from Outperform at William BlairKaruna Therapeutics downgraded to Market Perform from Outperform at William Blair
Wedbush
$330.00
Hold
0.06%
Upside
Downgraded
12/22/23
Karuna Therapeutics downgraded to Neutral from Outperform at WedbushKaruna Therapeutics downgraded to Neutral from Outperform at Wedbush
Deutsche Bank
$330.00
Hold
0.06%
Upside
Downgraded
12/22/23
Analysts Offer Insights on Healthcare Companies: Clene (NASDAQ: CLNN) and Karuna Therapeutics (NASDAQ: KRTX)
Piper Sandler
$330.00
Hold
0.06%
Upside
Downgraded
12/22/23
Karuna Therapeutics downgraded to Neutral from Overweight at Piper SandlerKaruna Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Best Analysts Covering Karuna Therapeutics

Which Analyst Should I Follow If I Want to Buy KRTX and Sell After:
1 Month
Jason GerberryBank of America Securities
Success Rate
3/4 ratings generated profit
75%
Average Return
+11.07%
reiterated a buy rating 7 months ago
Copying Jason Gerberry's trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +11.07% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Jason GerberryBank of America Securities
Success Rate
3/4 ratings generated profit
75%
Average Return
+31.20%
reiterated a buy rating 7 months ago
Copying Jason Gerberry's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +31.20% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Esther HongLoop Capital Markets
Success Rate
3/3 ratings generated profit
100%
Average Return
+71.83%
reiterated a buy rating a year ago
Copying Esther Hong's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +71.83% per trade.
2 Years
Esther HongLoop Capital Markets
Success Rate
3/3 ratings generated profit
100%
Average Return
+141.53%
reiterated a buy rating a year ago
Copying Esther Hong's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +141.53% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KRTX Analyst Recommendation Trends

Rating
Nov 23
Dec 23
Jan 24
Feb 24
Mar 24
Strong Buy
14
12
10
0
0
Buy
12
12
10
2
0
Hold
0
14
16
20
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
38
36
22
9
In the current month, KRTX has received 0 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. KRTX average Analyst price target in the past 3 months is $330.00.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

KRTX Financial Forecast

KRTX Earnings Forecast

Next quarter’s earnings estimate for KRTX is -$2.73 with a range of -$3.18 to -$2.16. The previous quarter’s EPS was -$3.01. KRTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.45% of the time in the same period. In the last calendar year KRTX has Underperformed its overall industry.
Next quarter’s earnings estimate for KRTX is -$2.73 with a range of -$3.18 to -$2.16. The previous quarter’s EPS was -$3.01. KRTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.45% of the time in the same period. In the last calendar year KRTX has Underperformed its overall industry.

KRTX Sales Forecast

Next quarter’s sales forecast for KRTX is $6.63M with a range of $0.00 to $25.00M. The previous quarter’s sales results were $0.00. KRTX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year KRTX has Underperformed its overall industry.
Next quarter’s sales forecast for KRTX is $6.63M with a range of $0.00 to $25.00M. The previous quarter’s sales results were $0.00. KRTX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year KRTX has Underperformed its overall industry.

KRTX Stock Forecast FAQ

What is KRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Karuna Therapeutics’s 12-month average price target is $330.00.
    What is KRTX’s upside potential, based on the analysts’ average price target?
    Karuna Therapeutics has 0.06% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KRTX a Buy, Sell or Hold?
          Karuna Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 15 hold ratings and 0 sell ratings.
            What is Karuna Therapeutics’s price target?
            The average price target for Karuna Therapeutics is $330.00. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $330.00 ,the lowest forecast is $330.00. The average price target represents 0.06% Increase from the current price of $329.79.
              What do analysts say about Karuna Therapeutics?
              Karuna Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of KRTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis